Becton Dickinson and Company (BDX)
$149.43
$-3.83
(-2.50%)
As on 08-May-2026 16:00EDT
Market cap
$41,174 Mln
Revenue (TTM)
$21,365 Mln
P/E Ratio
26.1
P/B Ratio
1.6
Div. Yield
1.4 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$1,449 Mln
-
ROE
0.1 %
-
ROCE
3.6 %
-
Industry P/E
45.24
-
EV/EBITDA
11.8
-
Debt to Equity
0
-
Book Value
$86
-
EPS
$3.9
-
Face value
--
-
Shares outstanding
275,540,427
10 Years Aggregate
CFO
$28,585.00 Mln
EBITDA
$32,854.00 Mln
Net Profit
$11,716.00 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Becton Dickinson and Company (BDX)
| -23.0 | -3.6 | -27.6 | -10.6 | -16.2 | -8.5 | -0.7 |
|
BSE Sensex
| -8.7 | 3.6 | -7.5 | -4.2 | 8.2 | 9.5 | 11.9 |
|
S&P 100
| 6.4 | 14.0 | 7.7 | 35.2 | 24.6 | 13.9 | 15.0 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Becton Dickinson and Company (BDX)
| -14.5 | -6.9 | -4.1 | 3.7 | 1.9 | -6.8 | 22.2 |
|
S&P 100
| 18.7 | 29.0 | 30.8 | -22.1 | 27.6 | 19.3 | 29.5 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Becton Dickinson and Company (BDX)
|
149.4 | 41,174.0 | 21,365.0 | 1,138.0 | 9.9 | 4.6 | 26.1 | 1.6 |
| 84.3 | 146,869.7 | 45,134.0 | 6,276.0 | 15.4 | 12.2 | 23.6 | 2.9 | |
| 53.9 | 80,159.1 | 20,615.0 | 3,553.0 | 10.0 | 14.5 | 22.6 | 3.2 | |
| 171.2 | 124,327.0 | 24,778.0 | 3,689.0 | 18.7 | 7.1 | 34 | 2.3 | |
| 80.0 | 46,041.0 | 6,303.5 | 1,092.8 | 12.7 | 10.6 | 43.2 | 4.6 | |
| 560.1 | 44,183.2 | 4,446.1 | 1,095.2 | 23.5 | 70.3 | 41.2 | 29.4 | |
| 450.1 | 159,394.5 | 10,582.1 | 2,979.1 | 22.4 | 17.2 | 54.6 | 9.2 | |
| 285.5 | 112,685.5 | 25,270.0 | 3,337.0 | 14.8 | 15.1 | 34 | 5.0 | |
| 465.0 | 176,319.5 | 45,197.0 | 6,859.0 | 19.2 | 13.3 | 26.1 | 3.4 | |
| 355.1 | 34,861.5 | 3,770.6 | 449.3 | 16.3 | 5.1 | 45.2 | 2.2 |
Shareholding Pattern
View DetailsAbout Becton Dickinson and Company (BDX)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical... industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care Read more
-
President, CEO & Chairman
Mr. Thomas E. Polen Jr.
-
President, CEO & Chairman
Mr. Thomas E. Polen Jr.
-
Headquarters
Franklin Lakes, NJ
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Becton Dickinson and Company (BDX)
What is the current share price of Becton Dickinson and Company (BDX) Today?
The share price of Becton Dickinson and Company (BDX) is $149.43 (NYSE) as of 08-May-2026 16:00 EDT. Becton Dickinson and Company (BDX) has given a return of -16.17% in the last 3 years.
What is the current PB & PE ratio of Becton Dickinson and Company (BDX)?
The P/E ratio of Becton Dickinson and Company (BDX) is 26.08 times as on 08-May-2026, a 42 discount to its peers’ median range of 45.24 times.
The P/B ratio of Becton Dickinson and Company (BDX) is 1.62 times as on 08-May-2026, a 45 discount to its peers’ median range of 2.93 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
32.03
|
2.12
|
|
2024
|
41.09
|
2.71
|
|
2023
|
50.99
|
2.93
|
|
2022
|
35.90
|
2.53
|
|
2021
|
33.91
|
3.00
|
What is the 52 Week High and Low of Becton Dickinson and Company (BDX)?
The 52-week high and low of Becton Dickinson and Company (BDX) are Rs 213.08 and Rs 143.00 as of 10-May-2026.
What is the market cap of Becton Dickinson and Company (BDX)?
Becton Dickinson and Company (BDX) has a market capitalisation of $ 41,174 Mln as on 08-May-2026. As per SEBI classification, it is a Large Cap company.
Should I invest in Becton Dickinson and Company (BDX)?
Before investing in Becton Dickinson and Company (BDX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.